Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:49:16 EST Sun 14 Dec 2025
Enter Symbol
or Name
USA
CA



Q:CPIX - CUMBERLAND PHARMACEUTICALS INC - https://www.cumberlandpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CPIX - Q0.12.30·3.100.12.53+0.041.6102.62455872.51  2.66  2.41927.25  1.8516:10:03Dec 0815 min RT 2¢

Recent Trades - Last 10 of 587
Time ETExPriceChangeVolume
16:10:03Q2.530.041
16:10:03Q2.530.041
16:04:15Q2.530.041
16:04:08Q2.530.041
16:00:02Q2.530.041,087
16:00:02Q2.530.04325
16:00:02Q2.530.04161
16:00:02Q2.530.04300
16:00:02Q2.530.0418
16:00:02Q2.530.0427

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-08 09:05U:CPIXNews ReleaseCALDOLOR(TM) (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT
2025-11-04 17:00U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH
2025-10-28 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE
2025-10-20 09:05U:CPIXNews ReleaseCUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
2025-10-13 09:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS' VIBATIV(TM) ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
2025-10-01 09:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
2025-09-29 09:05U:CPIXNews ReleaseTABUK LAUNCHES VIBATIV(TM) FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA
2025-08-05 16:05U:CPIXNews ReleaseCumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
2025-08-04 09:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV(TM) 4-VIAL STARTER PAK
2025-07-29 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
2025-06-23 09:05U:CPIXNews ReleaseCumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
2025-05-27 16:05U:CPIXNews ReleaseNEW STUDY FINDS CALDOLOR(TM) SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
2025-05-13 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
2025-05-06 16:05U:CPIXNews ReleaseCumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
2025-04-29 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
2025-03-19 16:05U:CPIXNews ReleaseFIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
2025-03-04 16:05U:CPIXNews ReleaseCumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
2025-02-25 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
2025-02-18 07:30U:CPIXNews ReleaseVIBATIV(TM) RECEIVES MARKETING APPROVAL IN CHINA
2025-02-04 07:30U:CPIXNews ReleaseCumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease